Biophytis Announces the Design of its Phase 2 OBA Clinical Study in Obesity
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / May 14, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the...
Clinical Trial
DEA in Disarray: MMJ BioPharma and Other Companies Mount Legal Battle Over Marijuana, Psychedelics, and Violation of Constitutional Rights
DEA FACES FOUR FEDERAL DISTRICT COURT SUITS CLAIMING DISARRAY and CONSTITUTIONAL VIOLATIONS WASHINGTON, D.C. / ACCESSWIRE / May 13, 2024...
Ainos Reports First Quarter 2024 Financial Results
Strategic focus on VELDONA and AI-powered point-of-care testing continues during 2024US$9M growth capital secured in May strengthens financial position for...
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
Click here to register for May 14 investor webcastCompany plans to file its Earnings Report on May 14, 2024 on...
PhotoPharmics Enrolls First 25 Patients in Pivotal Parkinson’s Disease Study to Improve Symptoms Beyond the Current Standard of Care
Groundbreaking at-home pivotal trial of a much-anticipated therapeutic device is underwaySALT LAKE CITY--(BUSINESS WIRE)--#medicaldevices--PhotoPharmics, the leader in specialized phototherapy for...
The Association of Cancer Care Centers and Flatiron Health Announce a Strategic Collaboration to Improve Study Data Capture
Partnership to enable cancer care centers to improve access and efficiency of clinical studies and researchNEW YORK--(BUSINESS WIRE)--Flatiron Health, a...
Empatica and McRoberts Partnership Achieves 200+ Endpoints and Opens Platform to External Algorithm Developers
BOSTON--(BUSINESS WIRE)--Empatica, a pioneer in digital biomarker development and patient monitoring driven by AI, and McRoberts, one of the leaders...
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA’s Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML
STONY BROOK, NY / ACCESSWIRE / May 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in...
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD
UK submission for national MAA review follows recently received positive opinion from Committee for Medicinal Products for Human Use (CHMP)...
Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024
LUND, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the...
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the...
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
– SENTI-202 is a potential first-in-class Logic Gated off-the-shelf CAR-NK cell therapy – – Initial clinical efficacy data expected by...
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
-Positive Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with BB-301 in the Phase 1b/2a...
Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
Interim data from initial dose escalation cohorts from Phase 1 CARDINAL trial of TERN-701 (allosteric BCR-ABL) in CML expected in...
Jasper Therapeutics Announces Briquilimab Development Program in Asthma
Expanding Portfolio of Mast Cell Programs with Plans to Initiate a Phase 1b/2a study in Patients with Asthma in Q4...
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF)...
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot Study
RECCE® 327 (R327) demonstrated >99% log reduction (>2.5 log reduction) in Mycobacterium abscessus lung infections using a nebulizer delivery methodR327...
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
PHILADELPHIA, May 13, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and...
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024 Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected...